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One of many risks facing HIV+ individuals is the development of kidney dysfunction and end
stage kidney disease (ESKD). A differential equation-based mathematical model was devel-
oped to assess the impact of antiretroviral therapy on the progression to kidney disease and
on reducing mortality due to kidney failure. Analytical and numerical predictions of long-term
HIV+ ESKD prevalence show that therapy can lead to either extremely low levels of disease
prevalence or increased prevalence, depending on drug efficacy levels and mechanisms of
action. Maintenance of HIV+ ESKD prevalence below one individual is possible with sufficient
efficacy (e.g., 99%) against the progression from AIDS to HIV+ ESKD and against entry to the
AIDS population, when the reduction in mortality in the AIDS and HIV+ ESKD populations is
modest (e.g., 10%). However, the concomitant decrease in mortality in the AIDS and HIV+
ESKD populations due to therapy is predicted to sustain greater disease prevalence.
Keywords: continuous ODE model, epidemic modeling, HIV infection, kidney disease, an-
tiretroviral therapy
1 Introduction
An infectious pathogen can have devastating effects on hu-
man populations. In 2020, the world witnessed the beginning
of the COVID-19 pandemic, caused by the novel coronavirus
SARS-CoV-2, resulting in over a million deaths as of October
2020 [10]. In 2018, Acquired Immune Deficiency Syndrome
(AIDS), caused by Human Immunodeficiency Virus (HIV),
claimed the lives of 470,000 individuals in sub-Saharan Africa
alone [22]. AIDS eventually leads to opportunistic infections
and death in almost all cases without therapy. Individuals with
HIV/AIDS are at risk for the development of kidney diseases,
including chronic kidney disease (CKD) and HIV-associated
nephropathy (HIVAN) [2, 17]. These conditions frequently
progress to end stage kidney disease (ESKD, or also called
end stage renal disease (ESRD)), in which individuals require
a life-long renal replacement therapy such as dialysis or kid-
ney transplantation [1]. CKD and ESKD are now consider-
able reasons for morbidity and mortality among those with
HIV infection [2]. A racial predilection is seen in HIVAN
in which a higher proportion are of African descent than any
other race; a recent study reported that almost 90% of indi-
viduals with ESKD due to HIVAN in the United States are
African-American [4, 12, 24].
The recommended treatment for individuals with HIV/
AIDS as well as for the HIV-infected who have ESKD (hence-
1Department of Mathematics & Statistics, Washington State University,
Pullman, WA, USA, 2Department of Mathematics & Statistics and School of
Biological Sciences, Washington State University, Pullman, WA, USA
forth referred to as HIV+ ESKD) is antiretroviral therapy
(ART), which is given as a combination of drugs that interferes
with virus replication. ART benefits individuals at risk for the
development of HIV-related kidney dysfunction and correlates
with a decreased incidence in HIVAN [11]. The therapy de-
creases mortality in HIV-infected individuals [21, 25]; in fact,
life expectancy with HIV on ART has been shown to be on par
with that of matched uninfected individuals [7]. Furthermore,
ART lowers the development of HIV+ ESKD and also reduces
mortality among those with HIV+ ESKD [1, 17]. While this
therapy is beneficial for those with HIV and those at risk for
or showing renal dysfunction, a concern has arisen recently
that the COVID-19 pandemic will result in disruption of an-
tiretroviral treatment for many individuals with HIV/AIDS. In
sub-Saharan Africa, bearing the majority of new HIV infec-
tions globally [6] and where 67.5% of the nearly 38 million
HIV+ individuals live [22], lockdowns from COVID-19 have
delayed access to HIV support services, and travel restrictions
have prevented health care workers from delivering ART to
communities [14, 16, 18]. Indeed, a recent mathematical mod-
eling study predicted that interruption in the supply of ART for
the HIV-infected population would lead to a 1.6-fold increase
in HIV-related deaths in a year [9].
In 2005, Schwartz et al. [19] published a model of the HIV+
ESKD epidemic that estimated the impact of ART on the de-
velopment of kidney disease. Even assuming 95% effective
therapy, the model projected a rise in HIV+ ESKD prevalence
in the future, as a result of the growth in the AIDS popula-
tion. Given that ART not only blocks entry to both AIDS
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and HIV+ ESKD, but it also reduces mortality in both pop-
ulations, a question that remains is what effect do the various
mechanisms of action and levels of ART have on the long-term
persistence of HIV+ ESKD? Here, we propose a new model,
which expands the previous model [19], to investigate the bal-
ance of the opposing effects of ART on the prevalence of HIV+
ESKD. We solve the model and analyze its long-term behav-
ior using stability analysis. We describe characteristics of the
steady state, and we also calculate the critical drug efficacy,
which we define as the minimum efficacy of ART that would
be required to maintain HIV+ ESRD prevalence below one
individual. With numerical simulations that demonstrate our
results, we show which ART mechanisms and at what levels
lead to decreased or increased HIV+ ESKD prevalence, and
we describe the trade-offs between the opposing population-
level consequences of ART on the epidemic dynamics. We
find that due to the rise in lifespans afforded by ART, we “lose”
the gains that result from ART’s effect on blocking the devel-
opment of renal disease, consistent with previous results from
the simpler model. We close with a discussion of the impli-
cations of these results, including in the context of decreased
access to ART during the COVID-19 pandemic.
2 Methods
2.1 Model
In the model of Schwartz et al. [19], the two populations, AIDS
(A) and HIV+ ESKD or nephropathy (N), were formulated as
a continuous system of ODEs as well as by a discrete system
of difference equations of the same two populations; both ap-
proaches yielded equivalent results. Here we expand upon the
ODE model to include greater complexity in the population
dynamics and actions of ART (Figure 1).
Specifically, we use the continuous ODE model and intro-
duce separate entry and exit terms in the A population. We
capture new individuals entering the A population at a constant
rate, b, and those dying exponentially due to AIDS at rate ρ,
or due to non-AIDS causes, at rate µA. We also include mor-
tality in the N population due to non-HIV+ ESKD causes, µN .
As in [19], mortality in N due to HIV+ ESKD is represented
by δ. The inclusion of separate mortality rates representing
deaths due to disease-related or disease-unrelated causes was
motivated by the vastly different mortality rates reported in the
literature (see Table 1). The current model presumes that all
patients with HIV+ ESKD arose from the AIDS population at
rate s and are thus subtracted from the AIDS population. Pa-
rameters representing antiretroviral therapy (ART) are ε, h, η
and j, and can take on values between 0 and 1 to represent
ART efficacy from 0% to 100%. We model ART that prevents
individuals from developing AIDS (either for HIV-infected in-
dividuals who do not have AIDS or HIV-uninfected individ-
uals taking ART as pre-exposure prophylaxis) with ε. ART
that blocks progression from AIDS to HIV+ ESKD is mod-
Figure 1: Schematic diagram of mathematical model
of HIV+ ESKD dynamics. In affected patients, AIDS
(A) progresses to kidney failure and nephropathy (N),
or HIV+ ESKD, and is represented by parameter s.
Antiretroviral therapy (ART) can halt this trend, rep-
resented by h. The entry into the AIDS population is
modeled by constant parameter b and can be reduced by
ART according to rate ε. Mortality due to AIDS is repre-
sented by ρ and can be mitigated by ART as represented
by η; those with AIDS who are treated and die from non-
AIDS-related causes are represented by µA. Likewise,
mortality due to HIV+ ESKD is represented by δ and
can be lessened by ART as represented by j; those with
HIV+ ESKD who are treated with ART and die due to
non-HIV+ ESKD-related causes are represented by µN .
Thus parameters representing ART are ε, h, η, and j.
eled by h. The effect of ART on reducing mortality among
those with AIDS is modeled by η and among those with HIV+
ESKD by j. The resulting model is as follows:
dA
dt
= (1 − ε)b − (1 − h)sA − (1 − η)ρA − µAA (2.1)
dN
dt
= (1 − h)sA − (1 − j)δN − µN N (2.2)
with A(0) = A0 and N(0) = N0.
2.2 Model Analysis
Theorem 2.1. Each solution of (A(t),N(t)) of the model with
non-negative initial conditions is non-negative for all t > 0.
Proof. Let X = (A,N)T and f (X) = ( f1(X), f2(X)). We can








(1 − ε)b − (1 − h)sA − (1 − η)ρA − µAA
(1 − h)sA − (1 − j)δN − µN N
]
. (2.3)
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Table 1: Model Parameters
Variables Description Initial Conditions Source
A(t) AIDS Population 31500 [3, 19]
N(t) AIDS Nephropathy (HIV+
ESKD) Population
166 [19]
Parameters Description Values Source
b Entry to AIDS population 21970 per year Fitted∗
ε Effect of ART on b Between 0 and 1 Varies
s Progression rate from AIDS to
HIV+ ESKD
0.01 per year [19]
h Effect of ART on s Between 0 and 1 Varies
ρ Death rate due to AIDS 1/6 per year Based upon a 6 year lifespan after AIDS diagnosis
without treatment [5, 8, 20]†
η Effect of ART on ρ Between 0 and 1 Varies
δ HIV+ ESKD mortality rate 0.67 per year Based upon a 1.5 year lifespan after diagnosis with
AIDS and HIV+ ESKD with no treatment [23]
j Effect of ART on δ Between 0 and 1 Varies
µA Natural mortality rate of AIDS
population
1/55 per year Based upon a 55 year lifespan after infection [13]
µN Natural mortality rate of HIV+
ESKD population
1/5 per year Based upon a 5 year lifespan after ESKD diagnosis
[15, 24]‡
∗Fitted from the equation A(t) and data [3] using other model values under the condition of no therapy.
†After AIDS diagnosis, presuming individuals with no therapy survive approximately 6 years [5, 8], with survival generally lower among Black
individuals [20].
‡Average life expectancy on dialysis is 5-10 years; the lower bound was taken due to the additional condition of HIV infection and higher
mortality seen in Black individuals [15, 24].
First, we have
A′(t)|A=0 = (1 − ε)b ≥ 0.
Since all non-ART parameters are positive, 0 ≤ ε, h, η, j ≤ 1,
and A′(t) ≥ 0 on the boundary, it follows that A(t) ≥ 0 for all
t. Next, we have
N′(t)|N=0 = (1 − h)sA ≥ 0.
By similar reasoning, it follows that N(t) ≥ 0 for all t. Hence
our model is biological meaningful and R2+ is positively invari-
ant. Therefore our model is mathematically well-posed. 
2.2.1 Analytical Solution































where k = (1 − h)s + (1 − η)ρ + µA and k′ = (1 − j)δ + µN .
2.2.2 Stability Analysis
The model has one equilibrium point (A∗,N∗),
A∗ =
(1 − ε)b
[(1 − h)s + (1 − η)ρ + µA]
N∗ =
(1 − h)s(1 − ε)b
[(1 − j)δ + µN][(1 − h)s + (1 − η)ρ + µA]
.
The Jacobian matrix of the system is
J =
[
−(1 − h)s − (1 − η)ρ − µA 0
(1 − h)s −(1 − j)δ − µN
]
.
The eigenvalues of the Jacobian matrix are
λ1 = −
(





(1 − j)δ + µN
)
. (2.5)
Negative eigenvalues imply (A∗,N∗) is a stable equilibrium.
Furthermore, using the analytical solution, for any initial con-







Hence (A∗,N∗) is a globally asymptotically stable equilib-
rium point. There is no ESKD-free equilibrium.
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2.2.3 Characteristics of the Equilibrium
We point out characteristics of the equations derived for the
steady state (A∗,N∗) that provide useful biological insights.
The ART parameter ε appears only in the numerator of each
steady state, and ART parameters η and j appear only in de-
nominators (specifically, η in each denominator, and j in the
N∗ denominator). Thus, when ART inhibits entry to the AIDS
population (0 < ε ≤ 1), A∗ will be reduced, and when ART
reduces mortality (0 < η ≤ 1 or 0 < j ≤ 1), A∗ or N∗ will
increase. ART parameter h is more interesting in that it ap-
pears in the denominator of A∗, and in both the numerator and
denominator of N∗, and hence h is a key parameter of interest
in this study.
2.2.4 Calculation of Critical Drug Efficacy, hc
Focusing our interest on HIV+ ESKD, we can determine the
condition required to reduce the steady state level below one
individual, or N∗ < 1. Setting N∗ < 1 and choosing our main
ART parameter of interest, h (the effect of ART on s, the rate
of progression from AIDS to HIV+ ESKD), we solve for h to
derive hc.
Setting N∗ < 1, we have
(1 − h)s(1 − ε)b
[(1 − j)δ + µN][(1 − h)s + (1 − η)ρ + µA]
< 1.
Solving for h gives
hc > 1 −
[(1 − η)ρ + µA][(1 − j)δ + µN]
s(1 − ε)b − s[(1 − j)δ + µN]
. (2.6)
We call this expression the critical drug efficacy hc needed
to block progression from AIDS to HIV+ ESKD such that the
HIV+ ESKD steady state is less than one individual. Recall
that h (like ε, η, and j) ranges from 0 to 1. When the second
term on the right hand side of (2.6) is much smaller than one,
then the critical efficacy will be difficult to achieve, as com-
pared to when the term is closer to one. In the latter case, there
are fewer constraints on the other parameter values required to
satisfy hc > 1. Thus, equation (2.6) provides the requirement
in terms of the other model parameters explicitly.
2.2.5 Model Parameterization
Values for parameters and initial conditions (Table 1) are taken
from the literature on Black individuals (in order to represent
the vast majority of those with HIV+ ESKD) in the United
States (US) or fitted as described below. We focus on the
US because data on AIDS and HIV+ ESKD were available
from two registries in the US, the Centers for Disease Control
and Prevention (CDC) [3] and the United States Renal Data
System (USRDS) [23], respectively. The data used were for
all Black individuals living with AIDS (from all sex and age
groups) from 1991-1995 (i.e., the time period before ART was
rolled out) [3] or calculated from new cases and deaths due to
AIDS Nephropathy annually [23] (as in [19]). The value for b
was determined by the best fit of the CDC data to the model
equation for A, using other model parameter values in Table 1,
under the condition of no therapy (i.e., ε = h = η = 0, as was
the case in 1991–1995 when ART was not yet available).
3 Results
In this section, we illustrate our model results by showing
simulations of the epidemic dynamics under conditions with
and without ART. Values for parameters and initial conditions
(shown in Table 1) are taken from the literature or fitted, as
described. First we provide the epidemic trajectories with-
out ART. In the absence of ART, both populations, AIDS (A)
and HIV+ ESKD (N), grow rapidly to steady state (Figure 2).
We are mainly interested in understanding how ART, which in
practice acts on b, s, ρ, and δ simultaneously, affects HIV+
ESKD prevalence. In this case, h, ε, η, and j > 0. It is in-
formative, however, to consider simple cases where ART is
blocking a single rate individually. Figure 3 shows the steady
state values reached for AIDS (A∗, left) and for HIV+ ESKD
(N∗, right) as each ART parameter (h, ε, η, and j) varies from
0 to 1 (i.e., representing 0 to 100% effective inhibition).
When ART completely inhibits the progression from AIDS
to HIV+ ESKD, h = 1. In this case (solid line), the AIDS (A)
population is very mildly increased, while the HIV+ ESKD
(N) population decreases to 0. Similarly, if ART completely
prevents individuals from developing AIDS, ε = 1. In this case
(dashed line), both populations, AIDS (A) and HIV+ ESKD
(N), decrease to 0.
ART also benefits infected individuals by decreasing mor-
tality, thereby lengthening lives. If ART fully prevents mortal-
ity due to HIV+ ESKD (δ), then j = 1. Under this condition
(dashed-dotted line), the steady state AIDS population (A) is
unchanged, but the HIV+ ESKD (N) population increases to a
steady state more than 4-fold higher than its previous level. In
fact, we can calculate the magnitude of the increase in N∗ as j





(1 − j)δ + µN
.
Thus, using the values in Table 1 and illustrated by comparing








Alternatively, when ART completely blocks AIDS mortal-
ity ρ, then η = 1. In this case (dotted line), both populations
increase, with HIV+ ESKD (N) increasing to an almost 7-fold
higher steady state level. We can likewise calculate the mag-
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Figure 2: Model simulation in the absence of ART.
AIDS (A) population (number of individuals), black.
HIV+ ESKD (N) population (number of individuals),
red. Parameter values and initial conditions are given
in Table 1, with h = ε = η = j = 0, representing
no ART. h, effect of ART on progression from AIDS
to HIV+ ESKD; ε, effect of ART on entry to AIDS; η,
effect of ART on AIDS mortality; j, effect of ART on
HIV+ ESKD mortality.




(1 − h)s + µA + ρ
(1 − h)s + µA + (1 − η)ρ
and thus using the values in Table 1 and illustrated by compar-





(1 − h)s + µA + ρ
(1 − h)s + µA
= 6.91.
Figure 3 also demonstrates how A∗ and N∗ change as a func-
tion of each ART parameter alone: ART inhibition of HIV+
ESKD development (by h) or mortality (by j) has no or little
effect on AIDS (unsurprisingly); ART inhibition of entry to
AIDS (by ε) appears linear in its decrease in A∗ as ε increases,
while inhibition of AIDS mortality (by η) appears exponential
in its growth of A∗ as η increases. Meanwhile, the effect of
increasing h or ε on N∗ appears as a linear decrease (as these
parameters reduce entry into the HIV+ ESKD or AIDS pop-
ulations, respectively); increasing j or η, which reduce mor-
tality, appear to exponentially increase N∗. Thus the percent
effectiveness of ART against different mechanisms of inhibi-
tion does not scale equally.
Realistically, treatment with ART acts along these mecha-
nisms simultaneously: it blocks the progression from AIDS
to HIV+ ESKD (h), it blocks the entry to AIDS (ε), it lowers
AIDS mortality (η), and it lowers HIV+ ESKD mortality ( j).
Using our model, we demonstrate the predicted effect of pairs
of ART parameters on reducing N∗ below 1, 50, 100, or 200
individuals. Figure 4 (top) shows the values of h and ε that re-
duce N∗ below these thresholds. Higher values of h and ε give
lower thresholds for N∗. When we consider ART that blocks
progression from AIDS to HIV+ ESKD (h > 0) with a simul-
taneous reduction in AIDS mortality (η > 0), however, we find
a different result. As η increases, a higher h is needed to main-
tain a low N∗ (Figure 4, middle). Equivalent results are seen
with ART that simultaneously blocks entry to AIDS (ε > 0)
and HIV+ ESKD mortality ( j > 0) (not shown). Thus, we
find that we “lose” the gains that result from ART’s effect on
blocking progression (h) or entry (ε). This can be explained
in that when ART decreases the mortality rate, longer lifes-
pans are achieved, maintaining prevalence of N. Finally, when
ART acts on all four mechanisms simultaneously (i.e., h, ε, η,
j > 0), lower N∗ thresholds can be reached (Figure 4, bottom).
Here we set h = ε and j = η. However, as before, increased
reductions in mortality (due to higher values of η and j) neces-
sitate greatly increased values of h and ε to maintain lower N∗
thresholds.
The results observed in Figure 4 (bottom) indicate that N∗
is less than one within a certain range of ART parameter val-
ues (i.e., above and to the left of the blue line). The condition
N∗ < 1 represents a steady state kidney disease prevalence
of less than one person. To exemplify this scenario, we ran
a time course simulation with ART values chosen from this
range. Figure 5 (top) shows the epidemic trajectories for the
parameter set with h = 0.99, ε = 0.99, η = 0.1, j = 0.1. This
simulation demonstrates an example in which equation (2.6)
is satisfied. The population trajectories indicate that HIV+
ESKD prevalence declines to N∗ < 1; in fact our model gives
N∗ = 0.16. In this scenario, ART works concurrently against
the four different mechanisms (i.e., the progression from AIDS
to HIV+ ESKD, entry to AIDS, AIDS mortality, and HIV+
ESKD mortality) without requiring any one mechanism to be
100% effective. Here, HIV+ ESKD prevalence is reduced be-
low one with very high efficacy of ART across entry modes (h
and ε) and modest efficacy to reduce deaths (η and j).
Using our model, we sought a single value across all four
ART parameters (i.e., hc = εc = ηc = jc) that gives N∗ < 1. We
found, however, that even 0.99 was insufficient, giving N∗ =
5.33 (Figure 5, bottom). In fact, for N∗ < 1, we would need
0.999 (giving N∗ = 0.06); even 0.995 gives 1 < N∗ < 2. Thus,
extremely high levels of ART efficacy across all mechanisms
(i.e., ≥ 99.9%) would be required to maintain N∗ < 1 with a
uniform ART efficacy.
4 Discussion and Conclusions
The mathematical model presented in this work provides a
framework for examining the dynamics of the epidemiology
of HIV+ ESKD and the role played by antiretroviral therapy
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Figure 3: Steady state levels (number of individuals) of AIDS (A∗, in black on left) and HIV+ ESKD (N∗, in red on right) as a
function of varying ART parameters between 0 and 1. h, effect of ART on progression from AIDS to HIV+ ESKD; ε, effect of
ART on entry to AIDS; η, effect of ART on AIDS mortality; j, effect of ART on HIV+ ESKD mortality. All other parameter
values and initial conditions are given in Table 1, and ART parameters other than the one being varied are set to 0.
(ART) for HIV infection. The study demonstrates the power
of simple modeling and straightforward mathematical anal-
ysis with numerical simulation to clarify the effects of ther-
apy on population dynamics, to illustrate the dominant trends,
and to elucidate the mechanisms behind these trends. This
model expands upon a previous model by taking into account
additional dynamics in both populations, in order to study
the effects of therapy across different mechanisms. We ana-
lyzed the model by finding the analytical solution, conducting
steady state and stability analyses yielding the single equilib-
rium point, and calculating the critical drug efficacy required to
maintain HIV+ ESKD prevalence below one individual. Our
numerical simulations showed epidemic trajectories of long-
term dynamics with no therapy, therapy that acts on different
mechanisms alone or in combination, and the therapeutic lev-
els required to drop the long-term kidney disease prevalence
below one individual.
Ultimately, the HIV+ ESKD burden (i.e., the steady state
level N∗) will depend on the combination of the efficacies of
ART across each of the four mechanisms: blocking progres-
sion from AIDS to HIV+ ESKD, reducing entry to AIDS, de-
creasing the mortality of AIDS, and decreasing the mortality
of HIV+ ESKD. While extremely low prevalence is possible
with ART, the effect of therapy on reducing mortality, thereby
extending the lifespans of those with AIDS and HIV+ ESKD,
is predicted to maintain persistence of kidney disease.
This result is consistent with the conclusions of a simpler
model [19]. However, the expanded model examined here
has several advantages over the previous work. In particu-
lar, Schwartz et al. modelled the entry and exit of AIDS (A)
with a single parameter, g, representing the overall growth of
the population. The overall growth rate can be affected by
ART, represented by the parameter m. The parameters g and
m were estimated using least squares data fitting of this equa-
tion to the CDC data. While the confidence in the parame-
ter estimation using this approach was high (due to small root
mean square errors), the model suffered from solutions that
were unbounded, which is biologically unrealistic. In the cur-
rent model, we resolve this issue by introducing separate entry
and exit terms in the A population. We use a constant entry
term, b, and an exponential decay term, ρ, motivated by the
ease of fitting to the available data. This approach also allows
us to model the effects of ART on each of these processes sep-
arately; we represent ART that prevents individuals from de-
veloping AIDS with ε, and ART that decreases the death rate
due to AIDS with η. Furthermore, we include a death rate of
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Figure 4: Level curves showing N∗ thresholds as ART parame-
ters vary. h, effect of ART on progression from AIDS to HIV+
ESKD; ε, effect of ART on entry to AIDS; η, effect of ART on
AIDS mortality; j, effect of ART on HIV+ ESKD mortality.
Top: N∗ as h and ε vary between 0 and 1. η = j = 0. For
each value of N∗, in order to maintain prevalence below that
threshold, the values of h and ε must be above and to the right
of the curve, respectively. Middle: N∗ as h and η vary between
0 and 1. ε = j = 0. For each value of N∗, in order to maintain
prevalence below that threshold, the values of h and η must be
above and to the left of the curve, respectively. Bottom: N∗ as
h, ε, j, and η vary between 0 and 1. ε = h and j = η. For
each value of N∗, in order to maintain prevalence below that
threshold, the values of h = ε and η = j must be above and to
the left of the curve, respectively.





















































































Figure 5: Epidemic trajectories in the presence of ART act-
ing across all mechanisms simultaneously. AIDS (A) popula-
tion (number of individuals), black. HIV+ ESKD (N) popula-
tion (number of individuals), red. Parameter values and initial
conditions are given in Table 1, unless otherwise indicated.
Top: Model simulation with h = 0.99, ε = 0.99, η = 0.1,
j = 0.1. Bottom: Model simulation with h = 0.99, ε = 0.99,
η = 0.99, j = 0.99. h, effect of ART on progression from
AIDS to HIV+ ESKD; ε, effect of ART on entry to AIDS; η,
effect of ART on AIDS mortality; j, effect of ART on HIV+
ESKD mortality.
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treated individuals with AIDS who die from non-AIDS causes
by µA. The Schwartz et al. model also neglected to include
mortality in the N population due to non-HIV+ ESKD causes,
µN , unlike the current model. A final advantage of the current
model is one of mutual exclusivity. Specifically, while both
models presume that all patients with HIV+ ESKD arose from
the AIDS population at rate s, the current model thus subtracts
these cases from the AIDS population, which ensures that each
of the populations A and N is mutually exclusive.
Given that the current study considers more demographics
in the AIDS population and more mechanisms of ART than
previous work, it allows us to investigate in greater detail the
role of AIDS demographics and the trade-off between the op-
posing effects of ART on kidney disease prevalence. Our re-
sults show that it is important to reduce entry to the AIDS
population (i.e., the rate of new AIDS cases). We also show
how higher efficacy of ART against entry to AIDS and progres-
sion from AIDS to HIV+ ESKD give a lower prevalence, but
greater efficacy of ART on reducing mortality gives a higher
prevalence, so in a sense, we “lose” the gains achieved by
blocking entry rates. In other words, while the effects of ART
along all its mechanisms of action benefit the individual pa-
tient, the reductions in mortality worsen the epidemic on the
population level, because the extension of lifespans increases
the risk pool of the epidemic. The implication of this finding
is that efforts that focus on prevention (to HIV/AIDS and to
HIV+ ESKD) should be promoted at the highest levels possi-
ble, for the sake of the individual as well as for the population.
Finally, we note that the overall effectiveness of ART will
be due to many factors in addition to the activity of the drugs.
Interruptions in access or delivery of ART stemming from the
COVID-19 pandemic will reduce the net effect of therapy, and
the degree of these interruptions will vary among countries
worldwide, with those affected most by HIV/AIDS possibly
suffering the greatest interruptions. The lack of adherence to
drug regimens by individual patients and the evolution of drug
resistance are factors that will lower the overall ART effective-
ness as well.
In future work, the model can be extended to include time-
varying parameters and calibrated with new epidemiological
data on HIV/AIDS and HIV+ ESKD. Further studies can also
determine how much treatment levels and the development of
renal disease have changed over time, include stochastic or hy-
brid modeling to examine small population dynamics resulting
from effective therapy, estimate the efficacy that ART has had
in slowing the progression from AIDS to kidney disease, and
use optimal control techniques to determine treatments that
would best stem the growth of this epidemic.
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